BioTuesdays

Author - Abby Hardy

Roth starts Millendo Therapeutics at buy; PT $35

Roth Capital Partners launched coverage of Millendo Therapeutics (NASDAQ:MLND) with a “buy” rating and $35 price target. The stock closed at $7.63 on Jan. 9. Millendo is a clinical-stage company focusing on the...

SVB Leerink starts Organogenesis at OP; PT $9

SVC Leerink initiated coverage of Organogenesis (NASDAQ:ORGO) with an “outperform” rating and $9 price target. The stock closed at $4.84 on Jan. 9. Organogenesis is a regenerative medicine company with a portfolio of...

Subscribe

Sign up to our weekly BioTuesdays newsletter.